O&G Vivas · Gynaecological health — benign gynaecology
Uterine fibroids — structured oral station (12 minutes)
FRANZCOG oral-format station on uterine fibroids: candidate applies the FIGO subclassification, runs the structured workup, builds a goal-directed medical-management ladder, and navigates the EMA ulipristal hepatotoxicity restrictions and the coexistence trap. Scored against the eight published RANZCOG oral domains.
On this page
Study tools
Target exams
Station format
4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply to every station: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport with patient, support person or colleague; respect; communication skills. You are marked on how you behave, not only what you know. [1]
Reveal the examiner script and model responsesShowHide
Opening prompt — "Classify her fibroids and tell me which one is driving the bleeding"
- "The submucosal fibroid projecting into the cavity with a small intramural component is FIGO type 1 — submucosal, less than 50 per cent intramural. The others are intramural, type 4."
- "FIGO type, not size, predicts the symptom. The type 1 submucosal fibroid is the one most likely driving her heavy bleeding — it distorts the endometrial venules and the myometrium over it cannot contract to clamp them. The intramural fibroids are more likely contributing to her bulk and girth."[2][3]
Probe 1 — "What is your initial workup?"
- "Exclude pregnancy first. Confirm uterine origin on bimanual exam; saline-infusion sonography to map the cavity component; FBC and ferritin — she is likely iron deficient; and a coagulation and von Willebrand panel if bleeding has been heavy since menarche."[1][3]
Probe 2 — "Her ferritin is 8. How does that change your plan?"
- "She has iron-deficiency anaemia from chronic heavy bleeding. I replete iron (oral or intravenous), and I can use a short course of medical therapy to stop the bleeding and shrink the fibroids ahead of any surgery — that improves her operative safety and reduces transfusion."[1]
Probe 3 — "Walk me through your medical options"
- "Tranexamic acid and NSAIDs first for cyclic control; the levonorgestrel intrauterine system — the most effective non-surgical option; a GnRH analogue with add-back for short-term volume reduction; or the modern oral GnRH antagonist relugolix combination (relugolix 40 mg plus oestradiol 1 mg plus norethindrone acetate 0.5 mg once daily), which avoids the flare and the separate add-back."[1][5]
Probe 4 — "Her friend took ulipristal acetate. Would you?"
- "Ulipristal works — PEARL showed around 90 per cent bleeding control — but the EMA restricted it after reports of serious liver injury, including transplants. It is now second-line and short-course: baseline and on-treatment liver function tests, contraindicated in pre-existing liver disease, and not recommended in women seeking fertility. I would not choose it first-line for this family-incomplete woman."[4]
Probe 5 — "She is frightened she will need a hysterectomy and lose her fertility. What do you say?"
This is a scored communication domain — demonstrate it out loud: [1]
- Move to her eye level, acknowledge the fear, and give the structure: "There are uterus-sparing options that fit your goal of preserving fertility. The submucosal fibroid can be removed through the cervix with a camera (hysteroscopic myomectomy), and we treat the bleeding medically first. A hysterectomy is not on the table for you unless everything else fails, and I will explain every option as we go."
- Offer a clear plan, a timeline, and a named contact between visits.[1]
References5ShowHide
- [1]American College of Obstetricians and Gynecologists (ACOG) Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228 Obstet Gynecol, 2021.PMID 34011888
- [2]Bajaj S, Gopal N, Clingan MJ, Bhatt S. A pictorial review of ultrasonography of the FIGO classification for uterine leiomyomas Abdom Radiol (NY), 2022.PMID 34581926
- [3]Puri K, Famuyide AO, Erwin PJ, Stewart EA, Laughlin-Tommaso SK. Submucosal fibroids and the relation to heavy menstrual bleeding and anemia Am J Obstet Gynecol, 2014.PMID 24080304
- [4]Yoon EL, Yuk JS. Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study J Clin Endocrinol Metab, 2021.PMID 33567071
- [5]Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy N Engl J Med, 2021.PMID 33596357